BRAIN Biotech and Akribion Therapeutics sign licensing deal for G-dase® E CRISPR-Cas tech.
BRAIN Biotech AG and Akribion Therapeutics GmbH have entered into an exclusive licensing agreement for the G-dase® E CRISPR-Cas technology, aiming to enhance treatments in oncology and other areas. The deal includes potential milestone fees up to EUR 92.3 million for BRAIN, based on Akribion's clinical development and market performance, alongside royalties on net sales. The agreement is subject to standard closing conditions.
October 31, 2024
4 Articles